March 13th 2023
Shilpa Gupta, MD, discusses bladder preserving strategies for unfit or young patients, trials assessing immunotherapy combinations, and results from the BLASST-1 trial presented at ASCO GU.
February 20th 2023
A retrospective study clarifies how the implementation of avelumab maintenance looks in real-world practice, according to an expert from Seattle Cancer Care Alliance.
First-line maintenance with avelumab in locally advanced or metastatic urothelial carcinoma yields efficacy that appears consistent between clinical and real-world settings.
February 18th 2023
Results from the phase 3 IMvigor130 trial reveal a trend towards overall survival improvement when atezolizumab plus chemotherapy was given to patients with locally advanced or metastatic urothelial carcinoma vs placebo.
An exploratory analysis indicates that overall survival did not improve with the use of single-agent atezolizumab in untreated locally advanced or metastatic urothelial cancer.
2 Clarke Drive Cranbury, NJ 08512